drugset / Trial / NCT01109264

Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia

NCT01109264

Phase 2 Completed 147 enrolled Jiangsu Simcere Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the clinical efficacy and safety of bendamustine hydrochloride versus chlorambucil for initial treatment of chronic lymphocytic leukemia

Timeline

Start
2010-03
Primary completion
2013-06
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bendamustine Small molecule 100 mg/m2 Intravenous
Comparator Chlorambucil Other / unclassified 0.4 mg/kg Oral